Targeting deubiquitinases for cancer therapy

Abstract

The ubiquitin-proteasome system assumes a critical role in numerous cellular processes, and among its components, deubiquitinases (DUBs) have emerged as essential regulators. With roughly 100 DUBs encoded within the human genome, these enzymes can be categorized into two main types: cysteine protease DUBs and metalloproteinase DUBs, based on the catalytic mechanism of the active site. DUBs exert significant influence over specific substrates implicated in cancer progression, establishing them as closely associated with various malignancies, including breast carcinoma, prostate cancer, and chronic myeloid leukemia. Consequently, the targeted inhibition of DUBs presents an enticing therapeutic strategy for cancer treatment. Here, we delve into the functional roles of DUBs in different cancer types and provide a thorough overview of the anticancer properties exhibited by DUB inhibitors. This knowledge will propel the development and clinical application of DUB inhibitors, opening promising avenues for tumor treatment.